Press releases
ADVITECH TO PRESENT AT THE 2008 TORONTO BIOFINANCE CONFERENCE
5 May 2008
| TSX VENTURE EXCHANGE: AVI | FOR IMMEDIATE RELEASE |
QUEBEC CITY, QUEBEC — May 5, 2008 — Advitech Inc. (“Advitech” or the “Company”) (TSX Venture Exchange: AVI) a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products, announces today that Mr. Renaud Beauchesne, President and Chief Executive Officer, will present at BioFinance 2008 on Wednesday May 7th at 4:30pm ET, in the Trinity III Room at the Toronto Marriott Eaton Centre.
ABOUT BIOFINANCE 2008: HTTP://WWW.BIOFINANCE.CA/
BioFinance 2008 is the Canadian Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia. BioFinance 2008 will be held on May 6 - 8, 2008 at the Toronto Marriott Eaton Centre.
ABOUT ADVITECH INC. WWW.ADVITECH.COM:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex® for the treatment of mild-to-moderate psoriasis.
Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L and IM technological platforms.
ABOUT GROWTH FACTORS:
Growth factors are proteins with multiple functions in the human body. Growth factors participate in the modulation of the immune responses and cell growth. Some growth factors are produced in the laboratory and used in biological therapy in extremely lucrative markets such as inflammatory diseases or skin care. However, synthetic production of growth factors is extremely expensive, which represents a major concern for product development.
Through an extensive research program, Advitech has mastered the ability to produce naturally milk derived growth factors at relatively lower cost than synthetic growth factors. The ability of Advitech to produce such growth factors opens up new market opportunities in the nutraceutical and pharmaceutical markets.
ABOUT WOUND HEALING:
According to Epsicom Business Intelligence Ltd., the global wound care market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factors based applications for wound healing represent more than 5% of the market, with an impressive 27% growth rate.
ABOUT DERMYLEX® WWW.DERMYLEX.COM:
Dermylex®, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex® for that type of psoriasis. Dermylex® is currently available in Canada and the U.S. (as BioDerm, Dermalyx®), as well as in France and Belgium (as Psopax®).
-30-
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Advitech Inc.
| Renaud Beauchesne, MBA President and Chief Executive Officer 418-686-7498, ext. 228 info@advitech.com | Serge Comeau Investor’s relations 514-862-4160 s.comeau@advitech.com |
pr-biofin2008-ang.pdf